Our Early Results for the Treatment of Acute and Subacute Iliofemoral Deep Vein Thrombosis with Rotational Thrombectomy Catheter

Tok, Mustafa; Tüydeş, Oktay; Kan, İrem İris; Yüksel, Ahmet; Yolgösteren, Atıf

doi:10.9739/uvcd.2014-41589

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study conducted, in only 20% of the patients who underwent catheter-mediated thrombolysis IVC filters were mounted and pulmonary embolism was not observed in any patient, and it was stated that it was safe and appropriate to place filters in selected cases instead of routine filter placement. 20,21 In another relevant study, 45% of the patients undergoing catheter-mediated thrombolysis after the insertion of a transient IVC filter had visible thrombus embolization in the filter and placement of an IVC filter for patients who would undergo catheter-mediated thrombolysis in order to be able to prevent the potential formation of pulmonary embolism. 21,22 In the present study, the risk of embolization that could develop was minimized by using routinely transient IVC filters in all patients prior to the procedure and as a result pulmonary embolism was not seen in any patient.…”

Section: Discussionmentioning

confidence: 99%

Initial experience with a new pharmacomechanical thrombectomy device for deep venous thrombosis: Report of 91 cases

Bozok

Tayfur

2019

Phlebology

View full text Add to dashboard Cite

Background To evaluate the efficacy and safety of pharmacomechanical thrombectomy using a new rotational thrombectomy device with additional thrombus-removal methods for deep venous thrombosis. Methods A total of 91 patients admitted to our tertiary center with symptomatic iliac, ilio-femoral, femoro-popliteal deep venous thrombosis and who underwent hybrid pharmacomechanical thrombectomy constituted the study group. Postinterventional color Doppler ultrasonography was repeated at 1st, 6th, and 12th months. Villalta scoring system was used to evaluate the patients for the development of post-thrombotic syndrome after deep venous thrombosis. The patient-reported severity of pain in the index leg was measured on a Likert scale. Results Of the 91 patients whose charts were reviewed, the location of thrombus was iliofemoral in 60 (65.9%) and femoropopliteal in 31 (34.1%) patients, respectively. Duration of symptoms was 5.62 ± 3.43 (range, 2–15) days. Technical success was observed in 82 patients (90.1%) at 3 months, in 77 patients (84.6%) at 6 months, and in 74 patients (81.3%) at 12 months. Villalta score was over 10 points in 15 of 17 patients whose Doppler US revealed venous occlusions, at 12 months, and in 8 patients with recurrent deep venous thrombosis. Post-thrombotic syndrome was detected in 18 patients in our study. Twelve (13.2%) of these 18 patients had mild, 5 (5.5%) moderate, and 1 (1.1%) severe PTS. In predicting predisposing factors in 18 patients with PTS, 13 patients (72.2%) had a Villalta score ≥10, 10 patients (55.6%) had experienced a delayed endovascular procedure (≥10 days), and 8 patients (44.4%) had recurrent deep venous thrombosis. Conclusion The endovenous pharmacomechanical thrombectomy with the Mantis thrombectomy device in the treatment of acute and subacute iliofemoral deep venous thrombosis is a promising approach in terms of efficacy and safety in the early period regarding reasonable and long-term prevention of post-thrombotic syndrome, development of pulmonary thromboembolism, and adequate venous system patency.

show abstract

Section: Discussionmentioning

confidence: 99%

Initial experience with a new pharmacomechanical thrombectomy device for deep venous thrombosis: Report of 91 cases

Bozok

Tayfur

2019

Phlebology

View full text Add to dashboard Cite

show abstract

“…24 Information about the outcomes of the Cleaner system is based on data from several recently published observational studies. [25][26][27][28][29] However, there are currently no randomized, controlled trial studying outcomes for this device in the literature. The outcomes of these observational case series in the literature are summarized in Table 1.…”

Section: Discussionmentioning

confidence: 99%

Midterm Outcomes of Pharmacomechanical Thrombectomy in the Treatment of Lower Extremity Deep Vein Thrombosis With a Rotational Thrombectomy Device

Yüksel

Tüydeş

2017

Vasc Endovascular Surg

View full text Add to dashboard Cite

show abstract

“…It can lead to pulmonary thromboembolism, venous gangrene, chronic venous insufficiency and post-thrombotic syndrome. 11 The most well-known factors in the etiology of lower-extremity deep vein thrombosis are genetic predisposition, malignancy, history of surgical operation, immobilization, trauma, bone fractures, long journeys and oral contraceptive use. 12 Nevertheless, there may also be other factors that play a role in the etiopathogenesis of deep vein thrombosis.…”

Section: Introductionmentioning

confidence: 99%

Association between vitamin D levels and lower-extremity deep vein thrombosis: a case-control study

Korkmaz

Ersoy²,

Yüksel

et al. 2021

Sao Paulo Med. J.

View full text Add to dashboard Cite

INTRODUCTIONVitamin D is a fat-soluble vitamin that is synthesized non-enzymatically in the skin and metabolized in the liver and kidneys. It arranges the immune response of the body, acts as a steroid hormone and plays a crucial role in mineral homeostasis and skeletal health. 1 Serum vitamin D levels in the range 30-60 ng/ml (75-150 nmol/l) are considered normal.Deficiency of vitamin D is associated with a variety of bone disorders (rickets, osteoporosis or osteomalacia), skin diseases and autoimmune disorders. 1,2 It also causes increased risk of cardiovascular diseases such as myocardial infarction (MI), heart failure and coronary artery disease. 2-5 Furthermore, deficiency of vitamin D has been reported in arterial diseases, including aortic aneurysm, peripheral arterial disease, arterial calcification and hypertension. [6][7][8][9] Deep vein thrombosis (DVT) is characterized by thrombus formation, usually in the lower-extremity deep venous system, which causes obstruction or occlusion of blood flow in veins. It is considered to be the third most common cardiovascular disease, after ischemic heart diseases and cerebrovascular events. 10 Although the medical and interventional treatment options for deep vein thrombosis have improved nowadays, it continues to pose a serious problem, especially in cases with inadequate treatment. It can lead to pulmonary thromboembolism, venous gangrene, chronic venous insufficiency and post-thrombotic syndrome. 11 The most well-known factors in the etiology of lower-extremity deep vein thrombosis are genetic predisposition, malignancy, history of surgical operation, immobilization, trauma, bone fractures, long journeys and oral contraceptive use. 12 Nevertheless, there may also be other factors that play a role in the etiopathogenesis of deep vein thrombosis.

show abstract

Our Early Results for the Treatment of Acute and Subacute Iliofemoral Deep Vein Thrombosis with Rotational Thrombectomy Catheter

Cited by 4 publications

References 0 publications

Initial experience with a new pharmacomechanical thrombectomy device for deep venous thrombosis: Report of 91 cases

Initial experience with a new pharmacomechanical thrombectomy device for deep venous thrombosis: Report of 91 cases

Midterm Outcomes of Pharmacomechanical Thrombectomy in the Treatment of Lower Extremity Deep Vein Thrombosis With a Rotational Thrombectomy Device

Association between vitamin D levels and lower-extremity deep vein thrombosis: a case-control study

Contact Info

Product

Resources

About